Investor Relations

Recent Event

Fourth Quarter 2024 Conference Call

Treosulfan Pivotal Study Results with Dr. Filippo Milano, MD

Email Alerts

Receive updates straight into your inbox

Sign up Today

Company Overview

Medexus Pharmaceuticals, Inc. is a leading innovative specialty pharmaceutical company with a strong North American commercial platform. Our product portfolio features leading products that address a variety of diseases, including allergy, dermatology, hematology, oncology and rheumatology.

The leading prescription products are Rasuvo and Metoject, unique formulations of methotrexate (auto-injector and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, an innovative allergy medication with a unique mode of action; IXINITY, for control & prevention of bleeding episodes & for perioperative management of patients with Hemophilia B; Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery; and Trecondyv, indicated in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (alloHSCT).

Investor Contact Information


Medexus Pharmaceuticals, Inc.
10 King Street East, Suite 600
Toronto, ON M5C 1C3
T: 877-422-5242

Investor Relations

Adelaide Capital
Victoria Rutherford
T: 480-625-5772

Direct Financial Strategies and Communication Inc.
Frank Candido
T: 514-969-5530